ELV vs. INCY: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ELV and INCY, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | ELV | INCY |
|---|---|---|
| Company Name | Elevance Health, Inc. | Incyte Corporation |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Providers & Services | Biotechnology |
| Market Capitalization | 78.92 billion USD | 16.96 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | October 30, 2001 | November 4, 1993 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of ELV and INCY by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | ELV | INCY |
|---|---|---|
| 5-Day Price Return | 9.64% | 3.53% |
| 13-Week Price Return | 0.76% | 26.88% |
| 26-Week Price Return | -19.42% | 43.44% |
| 52-Week Price Return | -30.62% | 28.42% |
| Month-to-Date Return | 8.47% | 2.41% |
| Year-to-Date Return | -4.99% | 25.74% |
| 10-Day Avg. Volume | 1.90M | 1.48M |
| 3-Month Avg. Volume | 2.27M | 1.84M |
| 3-Month Volatility | 43.67% | 32.56% |
| Beta | 0.53 | 0.82 |
Profitability
Return on Equity (TTM)
ELV
12.51%
Health Care Providers & Services Industry
- Max
- 24.86%
- Q3
- 15.79%
- Median
- 8.56%
- Q1
- 5.75%
- Min
- -1.64%
ELV’s Return on Equity of 12.51% is on par with the norm for the Health Care Providers & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.
INCY
24.09%
Biotechnology Industry
- Max
- 97.92%
- Q3
- 11.99%
- Median
- -19.30%
- Q1
- -51.29%
- Min
- -132.03%
In the upper quartile for the Biotechnology industry, INCY’s Return on Equity of 24.09% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
ELV
2.83%
Health Care Providers & Services Industry
- Max
- 11.56%
- Q3
- 5.45%
- Median
- 2.83%
- Q1
- 1.13%
- Min
- -1.71%
ELV’s Net Profit Margin of 2.83% is aligned with the median group of its peers in the Health Care Providers & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
INCY
18.99%
Biotechnology Industry
- Max
- 73.34%
- Q3
- 18.98%
- Median
- -12.96%
- Q1
- -105.72%
- Min
- -259.82%
A Net Profit Margin of 18.99% places INCY in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
ELV
4.43%
Health Care Providers & Services Industry
- Max
- 19.08%
- Q3
- 9.66%
- Median
- 4.77%
- Q1
- 2.46%
- Min
- -0.83%
ELV’s Operating Profit Margin of 4.43% is around the midpoint for the Health Care Providers & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
INCY
25.80%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 21.90%
- Median
- -13.30%
- Q1
- -109.94%
- Min
- -278.10%
An Operating Profit Margin of 25.80% places INCY in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | ELV | INCY |
|---|---|---|
| Return on Equity (TTM) | 12.51% | 24.09% |
| Return on Assets (TTM) | 4.51% | 15.81% |
| Net Profit Margin (TTM) | 2.83% | 18.99% |
| Operating Profit Margin (TTM) | 4.43% | 25.80% |
| Gross Profit Margin (TTM) | -- | 93.41% |
Financial Strength
Current Ratio (MRQ)
ELV
0.23
Health Care Providers & Services Industry
- Max
- 2.00
- Q3
- 1.51
- Median
- 1.29
- Q1
- 0.92
- Min
- 0.14
ELV’s Current Ratio of 0.23 falls into the lower quartile for the Health Care Providers & Services industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
INCY
2.85
Biotechnology Industry
- Max
- 16.97
- Q3
- 8.39
- Median
- 4.11
- Q1
- 2.64
- Min
- 0.74
INCY’s Current Ratio of 2.85 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
ELV
0.69
Health Care Providers & Services Industry
- Max
- 2.29
- Q3
- 1.24
- Median
- 0.74
- Q1
- 0.50
- Min
- 0.00
ELV’s Debt-to-Equity Ratio of 0.69 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
INCY
0.01
Biotechnology Industry
- Max
- 1.92
- Q3
- 0.79
- Median
- 0.12
- Q1
- 0.00
- Min
- 0.00
INCY’s Debt-to-Equity Ratio of 0.01 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
ELV
7.67
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.50
- Median
- 4.52
- Q1
- 2.12
- Min
- -4.44
ELV’s Interest Coverage Ratio of 7.67 is in the upper quartile for the Health Care Providers & Services industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
INCY
6.86
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.03
- Median
- -9.59
- Q1
- -65.05
- Min
- -163.11
INCY’s Interest Coverage Ratio of 6.86 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | ELV | INCY |
|---|---|---|
| Current Ratio (MRQ) | 0.23 | 2.85 |
| Quick Ratio (MRQ) | 0.23 | 2.55 |
| Debt-to-Equity Ratio (MRQ) | 0.69 | 0.01 |
| Interest Coverage Ratio (TTM) | 7.67 | 6.86 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
ELV
1.94%
Health Care Providers & Services Industry
- Max
- 5.93%
- Q3
- 2.59%
- Median
- 1.35%
- Q1
- 0.00%
- Min
- 0.00%
ELV’s Dividend Yield of 1.94% is consistent with its peers in the Health Care Providers & Services industry, providing a dividend return that is standard for its sector.
INCY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INCY currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
ELV
28.40%
Health Care Providers & Services Industry
- Max
- 185.33%
- Q3
- 74.82%
- Median
- 36.00%
- Q1
- 0.00%
- Min
- 0.00%
ELV’s Dividend Payout Ratio of 28.40% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
INCY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INCY has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | ELV | INCY |
|---|---|---|
| Dividend Yield (TTM) | 1.94% | 0.00% |
| Dividend Payout Ratio (TTM) | 28.40% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
ELV
14.62
Health Care Providers & Services Industry
- Max
- 40.02
- Q3
- 29.75
- Median
- 21.09
- Q1
- 14.18
- Min
- 7.05
ELV’s P/E Ratio of 14.62 is within the middle range for the Health Care Providers & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
INCY
19.39
Biotechnology Industry
- Max
- 40.44
- Q3
- 39.37
- Median
- 22.12
- Q1
- 15.76
- Min
- 3.48
INCY’s P/E Ratio of 19.39 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
ELV
0.41
Health Care Providers & Services Industry
- Max
- 3.15
- Q3
- 1.87
- Median
- 0.74
- Q1
- 0.27
- Min
- 0.09
ELV’s P/S Ratio of 0.41 aligns with the market consensus for the Health Care Providers & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
INCY
3.68
Biotechnology Industry
- Max
- 92.67
- Q3
- 41.36
- Median
- 8.45
- Q1
- 4.46
- Min
- 0.97
In the lower quartile for the Biotechnology industry, INCY’s P/S Ratio of 3.68 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
ELV
2.01
Health Care Providers & Services Industry
- Max
- 7.33
- Q3
- 4.45
- Median
- 2.52
- Q1
- 1.15
- Min
- 0.66
ELV’s P/B Ratio of 2.01 is within the conventional range for the Health Care Providers & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
INCY
3.16
Biotechnology Industry
- Max
- 22.72
- Q3
- 10.68
- Median
- 4.55
- Q1
- 2.44
- Min
- 0.59
INCY’s P/B Ratio of 3.16 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | ELV | INCY |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 14.62 | 19.39 |
| Price-to-Sales Ratio (TTM) | 0.41 | 3.68 |
| Price-to-Book Ratio (MRQ) | 2.01 | 3.16 |
| Price-to-Free Cash Flow Ratio (TTM) | 14.81 | 17.63 |